JP7253866B1 - トリアジン誘導体を含有する経口投与する製剤 - Google Patents

トリアジン誘導体を含有する経口投与する製剤 Download PDF

Info

Publication number
JP7253866B1
JP7253866B1 JP2022574839A JP2022574839A JP7253866B1 JP 7253866 B1 JP7253866 B1 JP 7253866B1 JP 2022574839 A JP2022574839 A JP 2022574839A JP 2022574839 A JP2022574839 A JP 2022574839A JP 7253866 B1 JP7253866 B1 JP 7253866B1
Authority
JP
Japan
Prior art keywords
formula
compound
vii
acid
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022574839A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023027198A5 (https=
JPWO2023027198A1 (https=
Inventor
真人 五味
健佑 堀内
甫享 森本
恵介 高垣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202211151791.9A external-priority patent/CN116514734A/zh
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JPWO2023027198A1 publication Critical patent/JPWO2023027198A1/ja
Priority to JP2023048827A priority Critical patent/JP7466731B2/ja
Application granted granted Critical
Publication of JP7253866B1 publication Critical patent/JP7253866B1/ja
Publication of JPWO2023027198A5 publication Critical patent/JPWO2023027198A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
JP2022574839A 2021-11-24 2022-11-22 トリアジン誘導体を含有する経口投与する製剤 Active JP7253866B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023048827A JP7466731B2 (ja) 2021-11-24 2023-03-24 トリアジン誘導体を含有する経口投与する製剤

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
JP2021189932 2021-11-24
JP2021189932 2021-11-24
JP2021191635 2021-11-26
JP2021191635 2021-11-26
JP2022006725 2022-01-19
JP2022006725 2022-01-19
JP2022012386 2022-01-28
JP2022012386 2022-01-28
JP2022017132 2022-02-07
JP2022017132 2022-02-07
JP2022027629 2022-02-25
JP2022027629 2022-02-25
JP2022046304 2022-03-23
JP2022046304 2022-03-23
JP2022142767 2022-09-08
JP2022142767 2022-09-08
CN202211151791.9 2022-09-21
CN202211151791.9A CN116514734A (zh) 2021-11-24 2022-09-21 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
PCT/JP2022/043092 WO2023027198A1 (ja) 2021-11-24 2022-11-22 トリアジン誘導体を含有する経口投与する製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023048827A Division JP7466731B2 (ja) 2021-11-24 2023-03-24 トリアジン誘導体を含有する経口投与する製剤

Publications (3)

Publication Number Publication Date
JPWO2023027198A1 JPWO2023027198A1 (https=) 2023-03-02
JP7253866B1 true JP7253866B1 (ja) 2023-04-07
JPWO2023027198A5 JPWO2023027198A5 (https=) 2023-08-02

Family

ID=85321709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022574839A Active JP7253866B1 (ja) 2021-11-24 2022-11-22 トリアジン誘導体を含有する経口投与する製剤
JP2023048827A Active JP7466731B2 (ja) 2021-11-24 2023-03-24 トリアジン誘導体を含有する経口投与する製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023048827A Active JP7466731B2 (ja) 2021-11-24 2023-03-24 トリアジン誘導体を含有する経口投与する製剤

Country Status (6)

Country Link
US (1) US20240148741A1 (https=)
EP (1) EP4289432A4 (https=)
JP (2) JP7253866B1 (https=)
KR (1) KR20230119022A (https=)
AU (1) AU2022333823A1 (https=)
WO (1) WO2023027198A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7273455B1 (ja) * 2022-01-19 2023-05-15 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
JP2023078413A (ja) * 2021-11-24 2023-06-06 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
LT4122926T (lt) 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
US11655240B1 (en) * 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
WO2023193818A1 (zh) * 2022-04-08 2023-10-12 湖北九康通生物医药有限公司 一种多取代三嗪烷类化合物的合成方法
WO2024031089A1 (en) 2022-08-05 2024-02-08 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
CN116554106A (zh) * 2023-04-28 2023-08-08 扬州市普林斯医药科技有限公司 一种6-氯-2-甲基-2h-吲唑-5-胺的制备方法
CN116589410B (zh) * 2023-05-29 2024-05-03 济南国鼎医药科技有限公司 一种6-氯-2-甲基-2h-吲唑-5-胺的合成方法
CN116621817B (zh) * 2023-07-20 2023-09-29 爱斯特（成都）生物制药股份有限公司 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途
CN117357531A (zh) * 2023-09-08 2024-01-09 湖北九康通生物医药有限公司 一种药物组合物、其制备方法和其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509140A (ja) * 1998-01-13 2002-03-26 アナディーズ・ファーマスーティカルズ，インコーポレイテッド トリアジン抗ウイルス化合物
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2022158528A1 (ja) * 2021-01-20 2022-07-28 国立大学法人北海道大学 抗ウイルス剤
WO2022212314A1 (en) * 2021-03-29 2022-10-06 Shireen Nature Company For General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2399910T3 (pl) * 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
CN103153968B (zh) 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
TW201331188A (zh) 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
PH12021552872A1 (en) 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN113801097B (zh) 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113666914B (zh) 2021-09-27 2022-06-07 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和用途
CN113773300B (zh) 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
CN113735838B (zh) 2021-09-27 2022-07-08 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113620888B (zh) 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和应用
EP4289432A4 (en) 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509140A (ja) * 1998-01-13 2002-03-26 アナディーズ・ファーマスーティカルズ，インコーポレイテッド トリアジン抗ウイルス化合物
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
WO2022158528A1 (ja) * 2021-01-20 2022-07-28 国立大学法人北海道大学 抗ウイルス剤
WO2022212314A1 (en) * 2021-03-29 2022-10-06 Shireen Nature Company For General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2022138987A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
JP7105430B1 (ja) * 2021-04-14 2022-07-25 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023078413A (ja) * 2021-11-24 2023-06-06 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤
JP7466731B2 (ja) 2021-11-24 2024-04-12 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤
JP7273455B1 (ja) * 2022-01-19 2023-05-15 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬

Also Published As

Publication number Publication date
KR20230119022A (ko) 2023-08-14
AU2022333823A1 (en) 2024-05-02
WO2023027198A1 (ja) 2023-03-02
JP7466731B2 (ja) 2024-04-12
US20240148741A1 (en) 2024-05-09
EP4289432A4 (en) 2025-01-15
EP4289432A1 (en) 2023-12-13
JPWO2023027198A1 (https=) 2023-03-02
JP2023078413A (ja) 2023-06-06

Similar Documents

Publication Publication Date Title
JP7253866B1 (ja) トリアジン誘導体を含有する経口投与する製剤
JP7105430B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
JP2021073241A (ja) 癌を処置する方法
CN116514734A (zh) 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
WO2023054292A1 (ja) トリアジン誘導体を含有する医薬組成物
AU2017214589A1 (en) Sulfonamide derivative and pharmaceutical composition containing same
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
KR20250004704A (ko) 바이러스 증식 저해 활성을 갖는 유라실 유도체 및 그들을 함유하는 의약 조성물
US20250025459A1 (en) Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
JP2024178473A (ja) ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
CN108929329B (zh) 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物
CN116782904A (zh) 含有三嗪衍生物的医药组合物
JP7701585B2 (ja) ウラシル誘導体を含有する製剤
RU2806042C1 (ru) Триазиновые производные, имеющие ингибиторную активность в отношении репликации вируса, и содержащая их фармацевтическая композиция
TWI916636B (zh) 新型冠狀病毒感染症治療用醫藥
HK40114521A (en) Pharmaceutical composition containing triazine derivative
AU2024307335A1 (en) Pharmaceutical composition containing uracil derivative
BR122023002208A2 (pt) Composições farmacêuticas compreendendo derivados de triazina tendo efeito inibidor de propagação de vírus, inibidores e usos
BR122023002208B1 (pt) Composições farmacêuticas compreendendo derivados de triazina para o tratamento e/ou prevenção de covid-19
WO2025074997A1 (ja) ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物
BR112022023272B1 (pt) Derivados de triazina tendo efeito inibidor de propagação de vírus e cocristal do mesmo com ácido fumárico
HK40098963A (zh) 治疗癌症的方法
JPWO2020045475A1 (ja) ピラゾロ［３，４−ｄ］ピリミジンの結晶

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221205

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230324

R150 Certificate of patent or registration of utility model

Ref document number: 7253866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250